Immune profiling company Immunai entered a research collaboration with Boehringer Ingelheim worth up to $15 million to identify novel T-cell targets across oncology and autoimmune disease. Immunai will apply its single-cell, multiomic immune profiling platform to large-scale patient datasets through 2027, aiming to detect T-cell dysfunction patterns as starting points for new drug discovery and development.